NZ586900A - Anhydrous polymorphic form b of bosentan and uses thereof - Google Patents

Anhydrous polymorphic form b of bosentan and uses thereof

Info

Publication number
NZ586900A
NZ586900A NZ586900A NZ58690009A NZ586900A NZ 586900 A NZ586900 A NZ 586900A NZ 586900 A NZ586900 A NZ 586900A NZ 58690009 A NZ58690009 A NZ 58690009A NZ 586900 A NZ586900 A NZ 586900A
Authority
NZ
New Zealand
Prior art keywords
bosentan
polymorphic form
mixture
anhydrous
anhydrous polymorphic
Prior art date
Application number
NZ586900A
Other languages
English (en)
Inventor
Dharmaraj Ramachandra Rao
Rajendra Narayanrao Kankan
Manjinder Singh Phull
Ashwini Amol Sawant
Original Assignee
Cipla Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cipla Ltd filed Critical Cipla Ltd
Publication of NZ586900A publication Critical patent/NZ586900A/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/69Benzenesulfonamido-pyrimidines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
NZ586900A 2008-01-01 2009-01-02 Anhydrous polymorphic form b of bosentan and uses thereof NZ586900A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN12MU2008 2008-01-01
IN836MU2008 2008-04-09
PCT/GB2009/000009 WO2009083739A1 (en) 2008-01-01 2009-01-02 Method of synthesis of bosentan, its polymorphic forms and its salts

Publications (1)

Publication Number Publication Date
NZ586900A true NZ586900A (en) 2012-10-26

Family

ID=40424567

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ586900A NZ586900A (en) 2008-01-01 2009-01-02 Anhydrous polymorphic form b of bosentan and uses thereof

Country Status (9)

Country Link
US (1) US8481730B2 (https=)
EP (2) EP2248805A3 (https=)
JP (1) JP5535082B2 (https=)
KR (1) KR20100113542A (https=)
AU (1) AU2009203174B2 (https=)
CA (1) CA2711043A1 (https=)
NZ (1) NZ586900A (https=)
WO (1) WO2009083739A1 (https=)
ZA (1) ZA201005014B (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004287875B2 (en) 2003-11-05 2011-06-02 Bausch + Lomb Ireland Limited Modulators of cellular adhesion
JP5535082B2 (ja) 2008-01-01 2014-07-02 シプラ・リミテッド ボセンタン、その多形形態及びその塩の合成方法
US8716477B2 (en) 2009-11-12 2014-05-06 Ranbaxy Laboratories Limited Crystalline forms of bosentan salts and processes for their preparation
JP5356323B2 (ja) * 2010-07-01 2013-12-04 富士化学工業株式会社 新規な非晶質ボセンタン及びその製造方法
WO2012002547A1 (ja) * 2010-07-02 2012-01-05 富士化学工業株式会社 ボセンタン固体分散体
JP5850576B2 (ja) * 2010-07-06 2016-02-03 富士化学工業株式会社 ボセンタン固体分散体
US20130245259A1 (en) 2012-03-16 2013-09-19 Natco Pharma Limited Process for the preparation of bosentan monohydrate
ITMI20120701A1 (it) 2012-04-27 2013-10-28 Dipharma Francis Srl Procedimento per la purificazione di un composto benzensolfonammidico
CA2879982C (en) 2012-07-25 2020-09-01 Sarcode Bioscience Inc. Lfa-1 inhibitor and polymorph thereof
WO2014033758A1 (en) * 2012-08-31 2014-03-06 Rao Davuluri Ramamohan 4-tert-butyl-n-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2(2-pyrimidinyl)-pyrimidine-4-yl)-benzen esulfonamide sodium
KR102004422B1 (ko) 2012-12-20 2019-07-26 제일약품주식회사 보센탄 일수화물의 제조방법, 이에 사용되는 신규 중간체 및 이의 제조방법
CN105102457A (zh) * 2013-02-21 2015-11-25 阿德弗里奥药品有限责任公司 {4,6-二氨基-2-[1-(2-氟苄基)-1H-吡唑并[3,4-b]吡啶-3-基]嘧啶-5-基}甲基氨基甲酸甲酯的形式
KR102259824B1 (ko) * 2018-07-24 2021-06-02 주식회사 마더스제약 보센탄을 함유한 약학 제제
US20250144095A1 (en) * 2022-02-03 2025-05-08 The Johns Hopkins University Compositions and methods for treatment of connective tissue disorders

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2086544C1 (ru) * 1991-06-13 1997-08-10 Хоффманн-Ля Рош АГ Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина
US6136971A (en) 1998-07-17 2000-10-24 Roche Colorado Corporation Preparation of sulfonamides
WO2001051919A2 (en) * 2000-01-07 2001-07-19 Transform Pharmaceuticals, Inc. High-throughput formation, identification, and analysis of diverse solid-forms
EP1254121B1 (en) * 2000-01-25 2006-02-01 F. Hoffmann-La Roche Ag Preparation of sulfonamides
AU2008247169B2 (en) * 2007-05-08 2013-09-12 Generics [Uk] Limited Polymorphic forms of bosentan
US8664390B2 (en) 2007-06-29 2014-03-04 Generics (Uk) Limited Process for the introduction of hydroxyethoxy side chain in bosentan
US20110014291A1 (en) 2007-10-11 2011-01-20 Actavis Group Ptc Ehf Novel Polymorphs of Bosentan
JP2011500780A (ja) * 2007-10-24 2011-01-06 ジェネリクス・(ユーケー)・リミテッド 新規結晶形
JP5535082B2 (ja) 2008-01-01 2014-07-02 シプラ・リミテッド ボセンタン、その多形形態及びその塩の合成方法
EP2240469A2 (en) * 2008-01-24 2010-10-20 Actavis Group PTC EHF Substantially pure and a stable crystalline form of bosentan
EP2294056A1 (en) * 2008-05-23 2011-03-16 Synthon B.V. Bosentan salts

Also Published As

Publication number Publication date
AU2009203174A1 (en) 2009-07-09
US8481730B2 (en) 2013-07-09
US20110015394A1 (en) 2011-01-20
ZA201005014B (en) 2011-03-30
JP5535082B2 (ja) 2014-07-02
EP2238118A1 (en) 2010-10-13
JP2011508767A (ja) 2011-03-17
CA2711043A1 (en) 2009-07-09
EP2248805A3 (en) 2011-02-23
AU2009203174B2 (en) 2014-01-30
EP2248805A2 (en) 2010-11-10
KR20100113542A (ko) 2010-10-21
WO2009083739A1 (en) 2009-07-09

Similar Documents

Publication Publication Date Title
NZ586900A (en) Anhydrous polymorphic form b of bosentan and uses thereof
NZ600119A (en) Process and intermediates for the preparation of 5-biphenyl-4-yl-2-methylpentanoic acid derivatives
NZ600110A (en) Process for the preparation of compounds useful as inhibitors of sglt
Amore et al. Fast, easy, solvent-free, microwave-promoted Michael addition of anilines to α, β-unsaturated alkenes: synthesis of N-aryl functionalized β-amino esters and acids
WO2009095933A3 (en) Improved and novel process for the preparation of bosentan
NZ707276A (en) Compounds useful in the synthesis of benzamide compounds
RU2015111236A (ru) Способ получения производного оксазола
ZA201003751B (en) Process for the synthesis of propargylated aminoindan derivatives
DK1877384T3 (da) Fremgangsmåde til fremstilling af eventuelt 2-substituerede 1,6-dihydro-6-oxo-4-pyrimidincarboxylsyrer
JOP20180126A1 (ar) عمليات جديدة من أجل تحضير منشطات محلقة غوانيلات قابلة للذوبان
WO2008100651A3 (en) Preparation of darifenacin and its salts
AR077332A1 (es) Procesos para la alquilacion de pirazoles
AU2013215796B2 (en) Method for preparing compound by novel Michael addition reaction using water or various acids as additive
CN104829575A (zh) 一种6-氟吡喃衍生物的制备方法
CN104844549A (zh) 一种7-溴吡喃衍生物的制备方法
CN104829574A (zh) 一种8-溴吡喃衍生物的制备方法
Xiong et al. Stereocontrolled synthesis of rosuvastatin calcium via iodine chloride-induced intramolecular cyclization
Pham et al. Stereoselective total synthesis of (2S, 3R)-3-hydroxypipecolic acid
JP6911062B2 (ja) ベムラフェニブの新規な製造方法
UA93860C2 (ru) Способ получения пиразолов, способ региоселективного алкилирования и применение фосфата или фосфоната b способе
EP3606905A1 (en) Cyclopropyl alkyl amines and process for their preparation
KR101226332B1 (ko) 2-(2-n-부틸-4-히드록시-6-메틸-피리미딘-5-일)-N,N-디메틸아세트아미드의 신규한 제조방법
CN104177273B (zh) 一种合成手性3-氨基-3-苯基-2-羟基羧酸酯化合物的方法
CN103012240A (zh) 一种阿托伐他汀钙的制备方法
CA2649506A1 (en) 2-alkenyl-3-aminothiophene derivative and process for producing thereof

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 02 JAN 2016 BY CPA GLOBAL

Effective date: 20130205

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 02 JAN 2017 BY CPA GLOBAL

Effective date: 20151231

LAPS Patent lapsed